Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
Zidavi is recommended by the Infectious Disease Society of America
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
